Discovered by BIOTEC research team together with the Medicines for Malaria Venture (MMV), the patented P218 compound was designed based-on 3-dimensional structures of malaria protein target, dihydrofolate reductase, in order to circumvent mutations that had led to resistance to pyrimethamine, […]
Recent Posts
- Thai Research on Antibody–Nanoparticle Technology for Dengue Treatment Selected under UNESCO’s International Decade of Sciences for Sustainable Development
02/25/2026 - BIOTEC NSTDA Welcomes Prof. Michele Suman as a Visiting Researcher to Strengthen International Collaboration in Food Safety Research
01/22/2026 - BIOTEC Welcomes Professors and Students from Texas A&M University for Lab Tour and Mycology Collaboration Discussions
01/06/2026